Human Claspin Biotinylated Antibody
R&D Systems, part of Bio-Techne | Catalog # BAF3310
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Biotin
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
E. coli-derived recombinant human Claspin
Phe1138-Ser1339
Accession # Q9HAW4
Phe1138-Ser1339
Accession # Q9HAW4
Specificity
Detects human Claspin in Western blots.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Applications for Human Claspin Biotinylated Antibody
Application
Recommended Usage
Western Blot
0.1 µg/mL
Sample: Recombinant Human Claspin
Sample: Recombinant Human Claspin
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Claspin
Claspin is a nuclear protein whose expression peaks during S and G2 phases of the cell cycle. Claspin is phosphorylated by ATR in response to DNA damage or replication stress. It functions in cell cycle checkpoint control by regulating the activation of Chk1 and BRCA1. Claspin contains three CKB motifs and two coiled coil regions. Over the range used for immunization, human and mouse Claspin share 72% amino acid sequence identity. DNA replication and DNA damage induce the phosphorylation of Claspin by Chk1-dependent mechanisms.
Alternate Names
CLSPN
Gene Symbol
CLSPN
UniProt
Additional Claspin Products
Product Documents for Human Claspin Biotinylated Antibody
Product Specific Notices for Human Claspin Biotinylated Antibody
For research use only
Loading...
Loading...
Loading...
Loading...